Coralie Bouillot

Passionnée par la médecine...donc la santé...et forcément l'innovation qui va avec :-) Pro vax, pro masques et antifakemed 😎#Eular #ERNReConnet #EMA

[Sjögren Europe @SjogrenEurope]

Our board member @CoBouillot contributed to a new systematic review in The Journal Of Rheumatology 📚.

The study shows a growing trend towards more patient-centered RCTs in #SjögrensDisease — a key step forward for research and care.

📄 Read here: https://t.co/jpN87THyO4

[Sjögren Europe @SjogrenEurope]

« Everything You Always Wanted to Know About Clinical Trials (But Were Afraid to Ask) »

Open and honest discussion with clinicians involved in research, patients and representatives from pharma.

🔗 Register now: https://t.co/4CxJsAkgyp

#WSD2025 #SjögrenDisease #Unmetneeds

[Coralie Bouillot @CoBouillot]

@AbrahamAubry @SjogrenEurope @eular_org @NeirinckMike We are not that far! Many many phase 3 ongoing, hope is permitted!

[Sjögren Europe @SjogrenEurope]

🌟Very important subject that deserves to be highlighted.

👉 Neurological issues in #Sjögren are often reported by patients as a major #unmetneed.

The webinar is free, open to everyone and will be moderated by our board member Coralie Bouillot

@alessia_alunno @CoBouillot

[Coralie Bouillot @CoBouillot]

@AbrahamAubry @SjogrenEurope @alessia_alunno Dear Abraham, will you be able to attend the webinar and ask your question? Otherwise, I will keep it and ask for you!

[RMD Open @bmj_rmdopen]

▶️ Sexual experience and functioning in male and female patients with Sjögren’s disease: a qualitative study

🧠💔 New study sheds light on the impact of #SjögrensDisease on sexual functioning in both women & men

⭐ 64% of women & 67% of men reported dysfunction.

🔺 Themes like chronic stress, invisible suffering & relationship dynamics highlight the need for holistic care.💬🛌

🔑 https://t.co/HBH1PC2gTQ

#Rheumatology #SexualHealth

[Sjogren's Syndrome Info @SjogrensTrials]

The relationship between neuropathic pain and lower urinary tract symptom scores in patients with primary Sjögren’s https://t.co/SlETGwy0vu

[@ReumatologiaJ @ReumatologiaJ]

🔥This NEW editorial highlights topical #cyclosporineA (CsA) as a key immunomodulatory treatment for #dryeye disease in #SjögrensSyndrome
👉https://t.co/vuTi8oMDL0
The importance of individualized treatment approaches is emphasized.

[Coralie Bouillot @CoBouillot]

Dites @aircaraibes , il paraît que vous refusez un voyage à Coline et son chien d’assistance??? C’est très très moche en plus d’être illégal @handichienscom #DoublePeine Ça s’arrête quand le combat pour faire JUSTE appliquer la loi?

[RMD Open @bmj_rmdopen]

🏥 The Newcastle Sjogren's Stratification Tool (NSST) identifies four symptom-based subtypes in Sjogren's disease, but understanding their stability over time is crucial for broader clinical adoption and trial design
📊 Analysis of 511 patients across two cohorts showed ~60% maintained their subtype over time, with high symptom burden being most stable (70%). Subtype stability was best predicted by initial baseline probability scores, complemented by C4 levels, antidepressant use, and comorbidity burden
🔬 The findings support that these symptom-based subtypes reflect genuine pathobiological endotypes, suggesting potential value for stratified approaches in drug development and clinical management

🔑 https://t.co/0mQky7uWCd

[Ana Vieira @SjogrenpowerAna]

https://t.co/qwbhdmnPne

[Plateforme MR AP-HP.Université Paris-Saclay @RareParisSaclay]

Le projet NECESSITY, soutenu par l'UE, vise à améliorer les traitements pour les patients atteints de Sjögren via de nouveaux critères d'évaluation, des biomarqueurs prédictifs, et un essai clinique multicentrique. Plus d'infos : https://t.co/RDFgXs2mDp @SjogrenSyndrome

[RMD Open @bmj_rmdopen]

🚨 Conception in women with primary Sjögren′s disease (pSS)

▶️ Assisted reproductive technology use does not seem much higher in women with pSS
▶️ Prospective and preconceptional follow-ups for cases and controls are needed 🔑

@GregoireMDF

🗝️ https://t.co/5xFJhwLhey

[Alessia Alunno @alessia_alunno]

📣To all physicians and health professionals involved in the care of people with RMDs!

Are you aware of the #cardiovascular risk of your patients and of @eular_org recommendations on this topic?

Take this 10-minute survey and pls repost! Thanks!

👉🏻 https://t.co/kXrbCmLU7U

[NatRevRheumatol @NatRevRheumatol]

#ResearchHighlight | JAK inhibitors improve RA pain
#pain #rheumatoidarthritis #therapy
Read the original article here: https://t.co/0bopQeHWjK

[Cuoghi Edens @CuoghiE]

Are you a #Lupus parent? Are you a teen or young adults with #SLE?
We have a research study for you! https://t.co/djpjksf5II

#lupuswarrior #curelupus #kidsgetlupustoo #lupusawareness #lupie #spoonie #rheumtwitter

[Peter Boyd @fibrofella]

Join myself and @SouzMakri as we host an exceptional #WAD #WorldArthritisDay webinar on the theme of Informed Choices, Better Outcomes.
Three outstanding speakers & an engaged Q&A session

[Sjogren's Syndrome Info @SjogrensTrials]

#SS | A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome | Recruiting | 12 locations in United States | #clinicaltrials | https://t.co/le8xPhG71f

[RMD Open @bmj_rmdopen]

Web-Based Ecological Momentary Assessment Tool — The Future of #Sjögren’s Disease Clinical Practice?

📱 Daily ESSPRI Assessments

✅ High Usability
📊 Accurate Symptom Tracking
📉 Captures Significant Day-to-Day Variability

🔓 https://t.co/usFFvb78aB

[Dr. John Cush @RheumNow]

2023 EULAR Recommendations on Management of Fatigue

A 2023 EULAR task force has made recommendations to the approach and management of fatigue in patients with inflammatory rheumatic and musculoskeletal diseases (I-RMDs).

https://t.co/t74IKmead2